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Stroke is a leading cause of death and disability in the USA. Up to 60% of patients do not fully recover despite intensive physical
therapy treatment. N-Methyl-D-aspartate receptors (NMDA-R) have been shown to play a role in synaptic plasticity when activated.
D-Cycloserine promotes NMDA receptor function by binding to receptors with unoccupied glycine sites. These receptors are
involved in learning andmemory.We hypothesized thatD-cycloserine, when combinedwith robotic-assisted physiotherapy (RAP),
would result in greater gains compared with placebo + RAP in stroke survivors. Participants (𝑛 = 14) were randomized to D-
cycloserine plus RAP or placebo plus RAP. Functional, cognitive, and quality-of-life measures were used to assess recovery. There
was significant improvement in grip strength of the affected hand within both groups from baseline to 3 weeks (95% confidence
interval for mean change, 3.95 ± 2.96 to 4.90 ± 3.56N for D-cycloserine and 5.72 ± 3.98 to 8.44 ± 4.90N for control). SIS mood
domain showed improvement for both groups (95% confidence interval formean change, 72.6± 16.3 to 82.9± 10.9 forD-cycloserine
and 82.9 ± 13.5 to 90.3 ± 9.9 for control). This preliminary study does not provide evidence that D-cycloserine can provide greater
gains in learning compared with placebo for stroke survivors.
1. Introduction
An estimated 750,000 Americans suffer a stroke annually,
incurring estimated costs related to their care of approxi-
mately $56.8 billion [1]. Stroke is a leading cause of serious
long-term disability and the long-term effects of stroke
affect an estimated 6.4 million Americans [2]. In addition,
50–60% of stroke survivors exhibit some degree of motor
impairment and require at least partial assistance in activities
of daily living [3, 4]. The most common impairments that
limit functional status after stroke are upper limb motor
dysfunction, specifically hand function [5] and gait [6]. The
burden of stroke-related disability is predicted to increase
in the coming decades in proportion to the expansion of
the elderly population [7]. Although stroke case fatality has
declined, stroke incidence has not, leading to rising numbers
of stroke survivors.
After ischemic damage to motor areas of the brain,
patients experience some degree of spontaneous recovery
[8, 9], which has increased since the advent of interventions
implemented in the acute period after stroke: notably, use of
tissue plasminogen activator (TPA) to dissolve blood clots.
Of those stroke survivors who do not spontaneously recover,
more than 50%will experiencemotor deficits [10]. One of the
most common and enduring impairments following stroke
is loss of arm and hand function and considerable time and
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resources are often spent to restore upper limb movement
[5]. Recovery can often take many months and is not always
effective [8, 11, 12].
Associated recovery of motor function in the affected
upper limb can be incomplete in up to 60%of stroke survivors
despite intensive rehabilitation programs [13]. The current
standard for intense physical therapy (PT) most commonly
consists of neurofacilitation techniques and/or task-specific
training [14]. Implementation of intensive physical ther-
apy, such as constraint-induced movement therapy (CIMT),
poses a variety of logistical challenges, as it requires substan-
tial time for setup and administration of the therapy in a time-
limited environment [3]. Neurotherapy methods also involve
the use of extensive human resources to provide several hours
of treatment and may suffer from lack of treatment fidelity
due to variability in treatment techniques between therapists
[3, 4, 15]. Labor-intensive and costly therapy methods are
critical barriers to achieving optimal functional outcomes in
stroke survivors with motor impairments.
There is a great need to find new ways to enhance the
effectiveness of upper limb rehabilitation in patients fol-
lowing stroke. Activation of N-methyl-D-aspartate receptors
(NMDA-R) is important for inducing various forms of synap-
tic plasticity [16]. D-Cycloserine is an established antibiotic
drug for the chronic treatment of tuberculosis in humans.
Application of D-cycloserine can enhance certain models
of plasticity, including long-term potentiation [17], and has
recently been investigated as an augmentation therapy for
psychological treatment procedures [18]. Such improvements
might occur because D-cycloserine promotes NMDA recep-
tor functions by binding to receptorswith unoccupied glycine
sites and perhaps by selectively enhancing the activity of
NMDA-R [19, 20], which are critically involved in learning
and memory.
Therefore, promotion of NMDA receptor function by
administration of D-cycloserine at 100mg may modulate
NMDA receptor activity and has been suggested to improve
cognition in patients with Alzheimer’s disease [21, 22].
Compared to placebo, 50mg of D-cycloserine has been
shown to enhance therapeutic learning from exposure-based
cognitive-behavior therapy in patients with anxiety-related
disorders [18].
Two studies have tested D-cycloserine as an adjuvant
to rehabilitation of stroke-related impairment. Cherry et al.
[23] found no significant difference in motor performance
on a stability platform balance task (Lafayette Instrument,
model 16030L) or a simulated feeding task [24], when a single
dose of D-cycloserine (250mg) was compared to placebo
(250mg) over the course of one training day. Nadeau et
al. [25] posited that 50mg of D-cycloserine combined with
constraint-induced movement therapy would increase learn-
ing because of its potential of sodium-calcium influx through
NMDA-glutamate voltage-gated sodium-calcium channels,
which are crucial to learning. The D-cycloserine treatment
failed to yield greater learning and retention compared to
placebo.
A promising approach to improving upper extremity
motor function utilizes repetitive task practice (RTP) and
behavioral shaping along with constraint of the less affected
limb, known as constraint-induced movement therapy [26].
Two fundamental limitations of CIMT are the time necessary
to deliver and oversee training and the excessive time during
which the less affected limb must be constrained. RTP, in
the context of CIMT, appears to be effective in improving
upper extremity motor function of patients with stroke [26].
Alternative approaches, such as robotic-assisted physiother-
apy (RAP), have also been investigated as a delivery method
to improve upper extremity motor function using repetitive
task practice. Recent evidence suggests that improvements
in upper extremity motor function, daily task performance,
and quality of life are seen during a robotic-assisted physical
therapy regimen [27].
Cognition plays an important role in performing motor
skills [28]; however, the role of cognition during physical
therapy treatment is unclear. Motor learning involves more
than storing sensory and motor information that arises as a
consequence of movement. Skill learning is highly cognitive,
and the cognitive processes that subserve movement must be
practiced. D-Cycloserine has been shown to have an effect
on procedural learning processes [29]. Procedural motor
learning most commonly entails acquiring novel movement
patterns, which is also the main objective in rehabilitation
of motor deficits after stroke. Deficient procedural motor
learning could therefore contribute to incomplete recovery of
motor functions in the chronic poststroke phase.
The purposes of this pilot study were to (1) evaluate the
safety and tolerance of D-cycloserine + RAP over three weeks
of study participation for stroke survivors and (2) evaluate
whether D-cycloserine + RAP improved grip strength, Box
and Block test (BBT) performance, daily robotic weighted
scores, and health related quality-of-life (HRQL) scores,
when compared to placebo + RAP over three weeks of study
participation for stroke survivors.
2. Methods and Materials
2.1. Subjects and Study Overview. Fourteen participants (3
males; 55.8 ± 13.1 years of age; time after stroke 391.2 ± 252.1
days) with chronic (greater than 3 months) ischemic stroke
were selected to participate in this double-blind, randomized
controlled trial.
The main entry criteria were a single unilateral ischemic
stroke 3 to 48 months prior to the study, age 18 to 95 years, at
least 10∘ of active wrist extension, at least 10∘ of thumb abduc-
tion/extension, and at least 10∘ of extension in at least two
additional digits [30]. Potential participants were excluded
if they scored less than 24 on the Minimental State Exami-
nation (MMSE) [31] or if physician-determined major med-
ical problems could interfere with participation. Additional
exclusion criteria were previously clinically documented
stroke; excessive pain in any joint of the paretic extremity;
a substantial decrease in alertness, language reception, or
attention; pregnancy or lactation; advanced systemic medical
disease; coexistent major neurologic or psychiatric disease;
orthostatic hypotension; concurrent use of drugs known
to interfere with the action of D-cycloserine; concurrent
enrollment in another stroke recovery investigation; or any
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2 hours of RAP 2 hours of RAP
Monday, medication given, and 2 hours of RAP
Wednesday, medication given, and 2 hours of RAP
Friday, no medication given, and 2 hours of RAP
Medication given (+) No medication given (−)
Wednesday Friday
Follow-up
2 hours of RAP
Figure 1: Experimental design and time course of the study. After completing baseline testing, therewere 6 visits at whichmedication (placebo
or D-cycloserine at 100mg dose) was dispensed. Dosing was oral and twice weekly (Monday andWednesday) throughout the study.The study
design included one session per week (Friday) in which the drug was not dispensed. Volunteers received medication immediately preceding
the robotic training sessions. Final examination was administered on Day 30. + indicates medication given and − indicates no medication
given. RAP: robotic-assisted physiotherapy.
contraindication to D-cycloserine. The choice of restricting
the time frame of stroke to at least 3 months after stroke was
intended to ensure that acute stroke medical issues would
have stabilized. The choice of no more than 48 months after
stroke was intended to minimize the variance introduced
by late poststroke changes, for example, contractures and
psychosocial decline.
After informed consent was obtained, eligibility was
determined and qualified subjects were randomized in a 1 : 1
fashion to either D-cycloserine or placebo in a double-blind
manner. Computer-generated randomization schedules were
generated with envelopes connecting subject identification
to treatment arm assignment provided to an unblinded
pharmacist. Patients received either drug or placebo before
two (Monday andWednesday) of three treatments each week
for three weeks, with concomitant RAP during all treatment
sessions (Figure 1). Assessments were performed at baseline
(Day 0) and follow-up (Day 30). The robotic device recorded
outcomes during the nine training sessions that were used
to assess motor outcome. Local institutional review boards
approved all procedures.
2.2. Therapeutic Intervention. D-Cycloserine is an FDA
approved medication that does not require titrating. Infre-
quent side effects in patients on chronic dosing schedule
(who were generally chronically ill with tuberculosis) have
included drowsiness, headache, confusion, tremor, vertigo,
memory difficulties, paraesthesias, and seizures [32]. There
were six visits at which placebo or D-cycloserine at 100mg
dose was dispensed. Dosing was oral and twice weekly
(Monday and Wednesday) throughout the study (Figure 1).
The study design included one session per week (Friday)
in which the drug was not dispensed. The patients received
two doses of D-cycloserine (or placebo) per week, reducing
chance for tachyphylaxis (i.e., rapidly decreasing response to
a drug after administration of a few doses). Furthermore,
recent D-cycloserine psychotherapy trials have observed
more rapid within-training improvements than those receiv-
ing the placebo [18]; therefore, we anticipate that the current
dosing regimen allowed any within-training improvements
to be captured on Friday’s RAP sessions in the absence of
drug.
RAP was provided two hours per day (9 days in total), for
a total of 18 hours distributed over three consecutive weeks.
A standard RAP protocol was used across people using the
HandMentor Pro (KMI Inc., Tempe, AZ 85282). Each RAP
session began 20 minutes after pill ingestion and focused on
wrist/arm therapy. Volunteers were encouraged to exercise at
home, but no formal home-exercise routine was prescribed.
The robotic device uses computer-game-like training
programs for motor control plus one spasticity reduction
program. A study by Wolf et al. [33] contains a complete
description of the HandMentor Pro including the system and
air muscle assembly, program/training options, performance
tables, and daily game activity charts (please refer to Figure 2
in Wolf et al. [33]). The aim of the training programs is
to increase active range of motion (AROM) of wrist and
finger flexion and extension and improve the accuracy of
these actions. The two main training programs used were
balloon and thera-pong. The object of the balloon game is
to fly a balloon across the ocean while avoiding obstacles.
The aim of the thera-pong game is to defeat the opponent
in a simulated table tennis game by earning a higher score.
The volunteer uses their affected wrist to control an in-game
paddle (or balloon) by moving it vertically across the left side
of the screen and competes against a computer-controlled
opponent.
2.3. Behavioral Testing. Bilateral upper extremity motor
function was quantitatively assessed using the Box and
Block test and hand dynamometry. Both the affected and
unaffected sides were tested to allow comparison between
sides. Sustained attention was assessed using a test of rapid
visual information processing (RVIP) [34, 35]. Information
processing speed and episodic and working memory were
measured using the Display Enhanced Testing for Con-
cussions and mild traumatic brain injury (mTBI) system
(DETECT system, Zenda LLC, Atlanta, GA). Health-related
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quality of life was assessed by the 8 subscales and overall
stroke recovery rating of the Stroke Impact Scale (SIS) version
3.0 [36]. The functional outcome measures and computer-
based measures were performed at baseline (Day 0) prior to
treatment and again at follow-up (Day 30).
2.3.1. Upper Limb Motor Function. The primary outcome
measures used to assess changes in motor performance
included Box and Block test [37] and hand-grip strength
using a hand dynamometer. The Box and Block test was
chosen because it involves dexterous manipulation of objects
and voluntary motor control, which has been shown to
improve with upper limb recovery following stroke [38].
Hand-grip strength has been shown to correlate with clinical
scores of improved recovery [39]. Hand-grip strength was
assessed using the whole hand and defined as the average
of 3 trials using a calibrated Jamar dynamometer (Jamar
Dynamometer, Asimow Engineering Co., Santa Monica,
CA), with the elbow flexed to 90∘ and the forearm in a neutral
position.
2.3.2. Sustained Attention and Short-Term Working Memory.
Participants were given the rapid visual information process-
ing task (RVIP) [34, 35] which is a continuous performance
test lasting 7 minutes during which time participants are
required to monitor a continuous stream of digits, pre-
sented at the rate of 100 digits per minute, for prespecified
digit strings (e.g., 3-5-7, in consecutive order). Participants
respond to the target strings by pressing the spacebar on
a computer keyboard. Any two sequences were separated
by a minimum of 5 and a maximum of 30 digits. Correct
detection (“hits”) of target strings can be registered during
the last digit of a sequence or in the subsequent 1800
milliseconds. The average latency of correct detection and
the number of commission errors (false alarms to nontarget)
are also assessed. Correct detection and commission errors
are converted to the single detection variable termed target
sensitivity (A-prime) [40, 41]. Target sensitivity is an index
of perceptual discriminability of target stimulus from noise
(scores range from 0 to 1), whereas response bias indicates the
tendency to respond regardless of whether a target is present
(scores range from−1 to +1). Reaction timewas alsomeasured
and defined as the time taken to respond to an experimental
target.
2.3.3. Cognitive Function. The Display Enhanced Testing for
Concussions andmTBI system (DETECT) was used to assess
cognitive function. The tests include (1) Complex Attention,
(2)Go-No-Go, (3) Selective RemindingMemoryTest, and (4)
N-Back Working Memory Test [42].
The DETECT test measure included overall accuracy
and response times for the simple and complex attention
conditions and forN-Back 1 andN-Back 2 conditions. For the
Selective Reminding Test, these included the total number of
hits and false alarms, as well as reaction times for both the
immediate and delayed recall conditions. The accuracy of a
test was treated as a continuous variable.
Individual items were designed to be answered with a
dichotomous “yes” or “no” response. In addition to simplicity
and ease of use for the test taker, “yes and no” response
recognition has been validated and is equivalent to forced
choice response when examining recognition memory [43].
Performance was scored based upon response type (correct,
incorrect, and missing) and response time (to the hundredth
of a second). The Selective Reminding and N-Back test
items were presented for 2-second intervals. If no response
was logged within 2 seconds, the next item was presented.
The Go-No-Go and Complex Choice Reaction Time tests
were presented for 3 seconds and if no response was logged
within 3 seconds, the next item was presented.This approach
ensured shortened battery, while challenging the patient to
respond quickly, thereby evaluating potentially slow informa-
tion processing speed as an indicator of cognitive difficulty.
2.3.4. HRQL. The Stroke Impact Scale (SIS), version 3.0,
includes 59 items that comprise 8 domains: strength, hand
function, combined basic ADLs and instrumental ADLs
(ADL/IADL), mobility, memory and thinking, communica-
tion, social participation, and emotion and mood regulation.
An overall rating of stroke recovery also is included. Each
domain contains a general description of the type of question
that follows and a statement with a reference to a specific
time period (1, 2, or 4 weeks). Respondents score their
performance on a 5-point scale (i.e., “no strength” to “a lot
of strength”; “never” to “all of the time”). Duncan et al.
[36] have shown the SIS to be valid, reliable, and sensitive
to change, and other investigators also have concluded that
the SIS has good psychometric properties [44]. A 4.5-to-17.8-
point change in a domain score may represent a clinically
significant change [45].
2.3.5. Depressive Symptoms. Because depression is an impor-
tant influence on the quality of life of stroke survivors, the
Center for Epidemiologic Studies Depression (CES-D) scale
was also included to control for depressive symptoms when
investigating the association between ARM/RTP and health-
related quality-of-life indicators. In the CES-D scale, each
item is rated on a scale from 0 to 3; scores range from 0 to
60 with higher scores indicating more depressive symptoms.
A score of 16 or above indicates possible depression.
2.3.6. Robotic Weighted Score. The robotic device uses
computer-game-like training programs formotor control and
one spasticity reduction program. The two main training
programs used were balloon and thera-pong. For each cycle
of the balloon (see (1a)) or thera-pong (see (1b)) program, the
robotic controller generates aweighted score perminute.This
score is generated using numerous measurements, including
the number of successful flights of the balloon (or rallies in
table tennis) completed, the number of flights (or rallies)
attempted, the overall duration of the cycle (32.29 ± 2.36
minutes each), and overall score.The score value is calculated
based on the number of possible goals (i.e., number of
Rehabilitation Research and Practice 5
cycles assigned), number of goals achieved, start angle, and





















2.4. Statistical Analysis. Statistical analyses included both
nonparametric and 2-tailed parametric methods. Baseline
characteristics of the two treatment groups were evaluated
for differences using 𝑡-tests, with special attention being
paid to the statistical power to evaluate the probability of
type II error. Change scores were calculated by subtracting
baseline fromoutcome scores at week 3. Continuous variables
were compared by repeated measures ANOVA, followed
by post hoc ANCOVA testing in order to explore how
baseline performance influenced overall recovery measures
and whether baseline performance correlated with overall
performance on outcome measures of recovery. A significant
interaction between time and group would support the
hypothesis that DCS facilitates learning. For daily robotic
measures, missing data were imputed by carrying the last
measured value forward. If data were missing for measures
performed at baseline and follow-up, only available values
were used for statistical analysis. All analyses were performed
with a minimal level of significance set at 𝛼 = 0.05 using SPSS
Statistics Version 21.0 (SPSS Inc., Armonk, NY 10504).
2.4.1. Sample Size. Initial power estimates, adapted from
Chen et al. [46], anticipated a baseline BBT score of 29.6± 13.4
blocks (mean ± SD) and end-of-treatment BBT score of 35.6
blocks for subjects in the D-cycloserine + RAP group versus
33 blocks for those in the placebo + RAP group, suggesting
that 14 patients were required in each study arm to achieve
80% power at 𝛼 = 0.05. Data are expressed as mean ± SD
unless otherwise stated. A sample size of 14 for each study
arm was not feasible given the fiscal limitations inherent in
the preliminary study; instead, 7 volunteers were enrolled in
each study arm.
2.4.2. UE Motor Function, Cognition, and HRQL. Motor
function (BBT and hand-grip strength), cognition (A-prime
and DETECT), and HRQL (SIS and CES-D) were analyzed
using group (D-cycloserine + RAP, placebo + RAP) by
time (pre- and posttreatment) repeated measures ANOVA
comparing the average changes over time on independent
variables for the two treatment groups. This was followed by
a univariate ANCOVA analysis comparing the magnitude of
improvement between the treatment groups (D-cycloserine
+ RAP, placebo + RAP) across time (pre- and posttreatment)
with baseline performance as a covariate. To correct for
errors associated with multiple comparisons, 𝑝 values were
corrected using the false discovery rate method.
The partial Eta squared (𝜂
𝑝
2) effect size statistic (which
indicates the proportion of the effect and error variance, i.e.,
attributable to the effect) was obtained as part of the repeated
measures ANOVA and ANCOVA analysis. For repeated
measures ANOVA analysis, ≤0.10 is considered a small effect
size, 0.25 is a moderate effect size, and ≥0.40 is a large effect
size [47]. For ANCOVA analysis, ≤0.01 is a small effect size,
0.07 is a moderate effect size, and ≥0.19 is a large effect size
[47].
The odds of being in one group (e.g., success) relative
to the odds of being in a different group (e.g., failure) are
captured in the odds ratio (OR) statistic. Average SIS scores
were also analyzed using a 2× 2 odds ratio analysis comparing
the number of SIS categories that improved on average by
clinically significant amounts between the two groups and
by collapsing the individual number of positive outcomes
(≥10 improvement) across all subjects and comparing the
values between the two groups. OR ranges from 0 to∞. OR
> 1 indicates an increase in odds relative to the reference
group. OR < 1 indicates a decrease in odds relative to the
reference group. In general, ≤2 is a small effect size, 3 is
a moderate effect size, and ≥4 is a large effect size [48].
The Chi square (𝜒2) test was used to examine differences of
categorical variables. All Chi square (𝜒2) 𝑝 values reported
were corrected using the Yates continuitymethod.While𝜒2 is
ameasure of the significance of association between variables,
the phi squared (𝜙2) value is a measure of the degree of
association between the variables. It can be interpreted as an
effect size for𝜒2 analysis. In general,𝜙2 ≤ 0.04 is a small effect
size, 0.25 is a moderate effect size, and ≥0.64 is a large effect
size [47].
2.4.3. Robotic Weighted Score. Daily robotic measures were
analyzed using planned nested repeated measures ANOVA.
ANCOVA was used in a subsequent secondary exploratory
analysis to better understand the significant interaction
between treatment group and SIS hand domain change score.
Testing occurred over three weeks, and nested within each
week were three tests (two with medication on Monday and
Wednesday and one without on Friday, Figure 1).
3. Results
3.1. Subjects and Safety. A total of 124 patients were screened
of whom 14 (4 men, 10 women; 4 Caucasian, 10 African
American) were enrolled. The most common reasons for
screening failure were that the patient lacked sufficient wrist,
thumb, or digit active range of motion, was >4 years after
stroke (𝑛 = 6), or declined participation (𝑛 = 7). Of the 14
patients that completed testing, one participant in the placebo
+ RAP groupwas excluded from the analyses because Tukey’s
schematic box plot analysis [49] identified her as an outlier;
subsequent analyses were performed on 13 participants (3
men, 10 women; 3 Caucasian, 10 African American).
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Overall, at baseline, subjects were well matched across
the 2 treatment groups, although more women were enrolled
than men (Table 1). The D-cycloserine group consisted of
all women, whereas the placebo group consisted of 3 men
and 3 women (𝑝 = 0.033) and had significantly lower
unaffected hand-grip strength scores (23.6 ± 6.6 compared
with placebo 34.5 ± 5.9, 𝑝 = 0.011). The days after stroke
did not differ between treatment groups (𝑝 = 0.334), nor
did MMSE (𝑝 = 0.673) and CES-D (𝑝 = 0.185) scores
at baseline. An independent-samples 𝑡-test indicated that
baseline SIS scores were not significantly different from each
other between the two groups for any of the 8 SIS categories,
nor for overall stroke recovery (Table 1). Groups did not differ
in past medical history; however, 3 subjects noted health con-
ditions (hypertension, hypercholesterolemia, and/or diabetes
mellitus) for which no medications were listed. Overall the
D-cycloserine + RAP treatment was generally safe and well
tolerated. No serious adverse events occurred.
3.2. Behavioral Effects. Repeated measures ANOVA
(between-subjects factor: treatment group (D-cycloserine +
RAP, placebo + RAP); within subjects factor: time (pre- and
posttreatment)) revealed significant effects of time. When
average UE motor performance was examined, significant
gains in grip strength were seen from baseline to week
three for the affected hand, being 1.77 ± 4.14 newtons,




Table 2(a)). Changes in grip strength of the unaffected hand
were not significant at follow-up. No significant changes
were observed in the BBT of the affected or unaffected
hand. When average cognitive measures were compared
across all subjects, significant gains in reaction time were
seen from baseline to week 3, being −425.81 ± 450.30ms,




= 0.495; Table 2(a)). Changes in sustained attention and
working memory scores were not significant at follow-up.
When average HRQL measures were compared, significant
gains were seen in the SIS category evaluating mood and
regulating emotion from baseline to week 3, being 8.97




= 0.410; Table 2(a)). Overall changes in the remaining
7 SIS categories and stroke recovery were not significant
(Table 2(a)).
Repeated measures ANOVA also revealed a significant
main effect of treatment group for motor performance for




Table 2(b)) and a significant time × treatment group interac-
tion for the HRQL SIS stroke recovery domain (𝐹(1, 12) =
9.391, 𝑝 = 0.020, 𝜂
𝑝
2
= 0.461; Table 2(c)). No significant
main effect of treatment group for the BBT of the affected or
unaffected hand was observed.
To explore the effect of baseline performance on over-
all recovery, univariate ANCOVA (between-subjects factor:
treatment group (D-cycloserine ± RAP, placebo ± RAP);
covariate: baseline performance)was performed.The analysis
revealed a significant main effect of group on SIS hand




0.573; Table 3(a)) only. The average change in affected hand
use (SIS domain) was greater for the placebo + RAP (mean
improvement 13.3 ± 23.2, 47.1% improvement; 𝐹(1, 9) =
12.054,𝑝 = 0.013, 𝜂
𝑝
2
= 0.573, Table 3(a)) comparedwith the
D-cycloserine + RAP (mean improvement 10.0 ± 12.6, 41.2%
improvement). No significant main effect of treatment group,
time, or interaction was seen for the BBT or grip strength of
the affected or unaffected hand.
ANCOVA also revealed a significant main effect of
baseline performance of the CES-D (𝐹(1, 12) = 15.197,
𝑝 = 0.007, 𝜂
𝑝
2
= 0.628; Table 3(b)) and SIS categories
















0.508; Table 3(b)). Significant treatment group × baseline
performance interaction was only observed for affected hand
use (𝐹(1, 9) = 11.771, 𝑝 = 0.013, 𝜂
𝑝
2
= 0.567; Table 3(c)).
A significant main effect of baseline performance on CES-
D score improvement was also observed (𝐹(1, 9) = 15.197,
𝑝 = 0.004, 𝜂
𝑝
2
= 0.628; Table 3(b)).
To evaluate the potential clinical significance of the
changes in average SIS Scores, odds ratio analysis was
performed. For the D-cycloserine + RAP group, five of
the nine SIS/stroke recovery scores improved by at least
10 points (which is considered to be a clinically significant
improvement), while only one category improved by as
much for the placebo + RAP group. While there was no
significant association between treatment group and number
of SIS categories that improved (odds ratio: 0.10, 95% CI:
0.452–221.080, 𝑝 = 0.145), there was a strong degree of
association between the treatment group and number of
SIS categories that improved by the MCID: 4.5–17.8 points
(𝜙2 = 0.222, 𝑝 = 0.036) [45]. Individual change scores
were then collapsed across all SIS categories and positive
versus neutral scores compared using a 2 × 2 OR table.
Between the two groups, there was a significantly greater
number of ≥4.5–17.8 change scores for the D-cycloserine
+ RAP group compared with placebo + RAP group, being
44.4% and 24.1%, respectively (odds ratio: 0.40, 95% CI:
1.063–5.988, 𝑝 = 0.036), and a significant degree of
association between the two variables (𝜙2 = 0.045, 𝑝 =
0.020).
3.3. Secondary Exploratory Analysis. In order to better
understand the significant interaction between treatment
group and SIS hand domain change score as determined
by the ANCOVA, analysis of residuals was performed. D-
Cycloserine + RAP had an average residual of 10 ± 2.0, while
placebo + RAP had an average residual of 13.3 ± 20.4. How-
ever, upon comparing residuals of each participant, Tukey’s
schematic box plot analysis revealed that one participant in
the control group had a significantly higher weighted score
residual than the rest (mean residual: 7.92 ± 2.96) for both
the balloon and thera-pong game. When this participant was
removed from residual analysis, D-cycloserine + RAP had
an average residual of 10 ± 2.0, while placebo + RAP had an
average residual of 5 ± 0.0.
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Table 1: Characteristics and baseline assessment of study participants as a whole and by group (∗note that mean DETECT 𝑍-scores were
computed for 𝑛 = 6 and 𝑛 = 5 for DCS + RAP and placebo + RAP groups, resp., due to missing values resulting from technical issues with
the instrument). Hx: history; Tx: therapy; SIS: Stroke Impact Scale; TPA: tissue plasminogen activator.
Total D-Cycloserine + RAP Placebo + RAP
𝑝
(𝑛 = 13) (𝑛 = 7) (𝑛 = 6)
Age [mean (SD)] 55.8 (13.1) 57.7 (7.3) 53.7 (18.4) 0.608
Men/women 3/10 0/7 3/3 0.033
Caucasian/African American 3/10 1/6 2/4 0.459
Marital status [married/divorced/widowed/other] 6/2/1/4 4/0/1/2 2/2/0/2 0.814
Years of education completed 13.6 (4.0) 14.1 (2.1) 13.0 (5.6) 0.626
Days after stroke [mean (SD)] 391.2 (252.1) 456.6 (253.9) 315 (249.5) 0.334
Smoking Hx, >10 pack-years [yes, no] 1/12 1/5 1/6 0.915
Received TPA [yes, no] 4/9 3/4 1/5 0.349
Neurointerventional Tx [yes, no] 1/12 0/7 1/5 0.363
Baseline performance measures
MMSE [mean score (SD)] 29.2 (1.1) 29.3 (0.8) 29.0 (1.5) 0.673
A-prime (SD) 0.9 (0.05) 0.9 (0.0) 0.9 (0.0) 0.085
Reaction time [sec (SD)] 1248.1 (700.9) 1147.8 (644.5) 1365.2 (806.2) 0.599
DETECT [mean 𝑍-score (SD)]∗ 10.1 (0.1) 10.2 (0.0) 10.1 (0.1) 0.393
Grip strength, affected hand [newtons (SD)] 4.8 (3.5) 4.0 (3.0) 5.7 (4.0) 0.390
Grip strength, unaffected hand [newtons (SD)] 28.6 (8.4) 23.6 (6.6) 34.5 (5.9) 0.011
BBT, affected hand [blocks moved (SD)] 9.7 (6.9) 9.7 (7.9) 9.6 (6.2) 0.991
BBT, unaffected hand [blocks moved (SD)] 45.9 (9.9) 48.7 (12.5) 42.7 (4.7) 0.289
CES-D [mean scale score, Day 1/mean (SD)] 12.3 (7.9) 15.1 (6.5) 9.2 (8.8) 0.185
SIS sections [scaled score (SD, FDR reported)]
Strength 51.0 (14.4) 50.1 (13.2) 51.0 (17.0) 0.986
Memory 77.7 (18.3) 72.9 (19.7) 83.3 (16.5) 0.330
Mood 77.4 (15.4) 72.6 (16.3) 82.9 (13.5) 0.248
Communication 89.3 (16.8) 85.7 (22.3) 93.5 (6.2) 0.430
ADL/IADL 78.2 (17.2) 78.2 (19.9) 78.2 (15.2) 0.995
Mobility 70.0 (19.2) 64.6 (23.9) 76.3 (10.6) 0.297
Hand function 26.2 (21.2) 24.2 (29.6) 28.3 (4.1) 0.733
Social participation 62.7 (19.5) 53.6 (17.8) 73.4 (16.7) 0.064
Percent recovery 53.5 (9.9) 50.7 (9.3) 56.7 (10.3) 0.298
Previous diagnoses
Hypertension [yes, no] 10/3 6/1 4/2 0.459
High cholesterol [yes, no] 7/6 4/3 3/3 0.817
Diabetes mellitus [yes, no] 3/10 1/6 2/4 0.459
Atrial fibrillation [yes, no] 0/13 0/7 0/6 —
Coronary artery disease [yes, no] 1/12 1/6 0/6 0.356
Prior stroke [yes, no] 1/12 1/6 0/6 0.356
Alcoholism [yes, no] 1/12 1/6 0/6 0.356
Substance abuse disorder [yes, no] 0/13 0/7 0/6 —
Medications
Hypertension [yes, no] 8/5 6/1 2/4 0.059
High cholesterol [yes, no] 6/7 4/3 2/4 0.433
Diabetes mellitus [yes, no] 3/10 1/6 2/4 0.459
Anticoagulant [yes, no] 6/7 5/2 1/5 0.053
3.4. Robotic Weighted Score. Nested repeated measures
ANOVA (between-subjects factor: treatment group (D-
cycloserine + RAP, placebo + RAP); two within-subjects
factors: time (week, three levels) and treatment distribution
(medication, no medication)) of the mean weighted balloon
game score revealed a significantmain effect of time across all




= 0.267; Figure 2(a)).
















































Figure 2: Robotic weighted score. Weighted scores on 6 times during which placebo or D-cycloserine (D-cycloserine) at 100mg dose was
dispensed. Across all subjects, mean weighted score on the (a) balloon game and (b) thera-pong improved significantly, from baseline to end
of week 1, to week 2, and to week 3. However, there were no significant differences according to treatment group or interaction for any of
these time intervals.
There was also a significant main effect of time across
all subjects for the mean weighted thera-pong score from




Figure 2(b)), in addition to a main effect of treatment within




were no significant overall week× treatment group, treatment
days × treatment group, or week × treatment day × treatment
group interactions for either therapeutic training program.
ANCOVA analysis was not performed as all patients began
RAP on the same difficulty level.
4. Discussion
This preliminary study aimed to evaluate safety, motor, and
quality-of-life effects of D-cycloserine + RAP in patients
with chronic stroke. D-Cycloserine + RAP was safe and
well tolerated. However, the main study hypothesis that
D-cycloserine + RAP was superior to placebo + RAP for
increasing upper limb motor function in adults with chronic
stroke was not supported. At four weeks, there was no
significant difference in primary or secondary outcomes.The
only significant group effect uncorrected for any covariates
was a relative improvement in grip strength of the affected
hand.This effect did not remain significant after adjusting for
baseline differences.Theonly significant group differencewas
observed in SIS hand function category for the affected hand
in the RAP + D-cycloserine group.
Several lines of evidence suggest that activation of N-
methyl-D-aspartate receptors (NMDA-R) is important for
inducing various forms of synaptic plasticity that are critically
involved in learning and memory. D-Cycloserine promotes
NMDA receptor function by binding to receptors with unoc-
cupied glycine sites and in addition perhaps by selectively
enhancing the activity of NMDA-R [50] and might be useful
for reversing deficits in function following stroke.
A recent study examined D-cycloserine + motor training
as a potential enhancer of motor learning in able-bodied and
stroke survivor participants [23]. Cherry et al. [23] found
no significant difference in motor performance on a stability
platform balance task (Lafayette Instrument, model 16030L)
or a simulated feeding task [24], when a single dose of
D-cycloserine (250mg) was compared to placebo (250mg)
over the course of one training day. In addition, a single
250mg dose of D-cycloserine failed to promote generaliza-
tion of motor training on an untrained motor task [23]. The
preliminary findings from Cherry et al. [23] evaluated the
effects of one 250mg dose of D-cycloserine on one day of
motor training, in hopes of activating NMDA-R mediated
LTP. However, unlike behavioral and psychiatric studies
that have found efficacy in a single dose of D-cycloserine,
motor learning may require repeated training exposure to
enhance learning [24, 51]. In a recent randomized controlled
trial provision of D-cycloserine (50mg given each treatment
day for up to ten weeks) failed to yield greater learning
and retention of functional improvement achieved through
therapy compared to placebo [25]. Our results support the
finding of Nadeau et al. in that D-cycloserine in the dosing
regime used plus repeated motor training sessions did not
lead to enhanced motor learning compared to placebo.
There are several possible interpretations as to why no
difference was observed between treatment arms on pri-
mary outcomes. The findings might indicate that increased
NMDA-ergic tone simply does not engage procedure learning
(i.e., those engaged in RAP) to the same extent as has
been shown with implicit memory [21] and visuospatial
learning [52] processes even though both engage NMDA-R
dependent LTP mechanisms. Despite NR2C concentrations
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Table 2: ANOVA table for (a) time, (b) treatment group, and (c)
time × treatment interaction for A-prime, reaction time, DETECT
𝑍-score, grip strength, BBT, CES-D, and SIS categories. There was a
significant main effect of time on reaction time, DETECT 𝑍-score,
grip strength of the affected hand, and CES-D score. There was a
significant main effect of treatment group on grip strength of the
unaffected hand only.Therewas a significant time× treatment group
interaction for SIS overall stroke recovery rating only.
(a) Repeated measures ANOVA (per visit) across all subjects
Source 𝐹 𝑝 𝑝-RFDR 𝜂
𝑝
2
A-prime 2.852 0.119 0.225 0.206
Reaction time 10.765 0.007 0.014 0.495
DETECT 𝑍-score 7.026 0.026 0.050 0.438
Grip strength, affected hand 19.839 0.001 0.002 0.643
Grip strength, unaffected hand 5.331 0.041 0.078 0.326
BBT, affected hand 0.022 0.884 1.670 0.002
BBT, unaffected hand 4.816 0.051 0.096 0.305
CES-D score 6.330 0.029 0.054 0.365
Stroke Impact Scale Category
Strength 0.414 0.533 1.007 0.036
Memory 5.594 0.037 0.071 0.337
Mood 7.653 0.018 0.035 0.410
Communication 0.634 0.443 0.836 0.055
ADL/IADL 4.133 0.067 0.126 0.273
Mobility 0.649 0.438 0.826 0.056
Hand function 5.325 0.041 0.078 0.326
Participation 2.810 0.122 0.230 0.203
Stroke recovery 0.971 0.346 0.623 0.081
(b) Repeated measures ANOVA (per group)
Source 𝐹 𝑝 𝑝-RFDR 𝜂
𝑝
2
A-prime 2.424 0.148 0.279 0.181
Reaction time 0.316 0.586 1.106 0.028
DETECT 𝑍-score 0.000 1.000 1.889 0.000
Grip strength, affected hand 1.493 0.247 0.467 0.120
Grip strength, unaffected hand 8.407 0.014 0.026 0.433
BBT, affected hand 0.043 0.840 1.587 0.004
BBT, unaffected hand 0.308 0.590 1.115 0.027
CES-D score 2.988 0.112 0.211 0.214
Stroke Impact Scale Category
Strength 0.287 0.603 1.139 0.025
Memory 0.141 0.714 1.349 0.013
Mood 1.841 0.202 0.382 0.143
Communication 0.093 0.767 1.448 0.008
ADL/IADL 0.009 0.924 1.746 0.001
Mobility 0.691 0.424 0.800 0.059
Hand function 0.211 0.655 1.237 0.019
Participation 2.793 0.123 0.232 0.203
Stroke recovery 2.909 0.166 0.299 0.209
(c) Repeated measures ANOVA (time × group interaction) across all
subjects
Source 𝐹 𝑝 𝑝-RFDR 𝜂
𝑝
2
A-prime 2.105 0.175 0.330 0.161
Reaction time 0.316 0.586 1.106 0.028
(c) Continued.
Source 𝐹 𝑝 𝑝-RFDR 𝜂
𝑝
2
DETECT 𝑍-score 0.633 0.447 0.844 0.066
Grip strength, affected hand 4.602 0.055 0.104 0.295
Grip strength, unaffected hand 2.060 0.179 0.338 0.158
BBT, affected hand 0.557 0.471 0.890 0.048
BBT, unaffected hand 2.585 0.136 0.257 0.190
CES-D score 0.216 0.651 1.230 0.019
Stroke Impact Scale Category
Strength 0.259 0.621 1.172 0.023
Memory 4.177 0.066 0.124 0.275
Mood 0.206 0.659 1.245 0.018
Communication 2.925 0.115 0.218 0.210
ADL/IADL 0.164 0.693 1.309 0.015
Mobility 1.014 0.336 0.634 0.084
Hand function 0.109 0.748 1.413 0.010
Participation 1.779 0.209 0.395 0.139
Stroke recovery 9.391 0.011 0.020 0.461
in hippocampal and neocortex interneurons [53, 54], human
in situ mRNA probes reveal very weak signal density in the
primary motor cortex [55]. Since the primary motor cortex
plays an integral role in activity dependent LTP [56], very
weak NR2C concentrations would limit the enhancing effects
of D-cycloserine on NMDA-R dependent LTP. Although the
specific mechanisms for RAP on NMDA-R dependent LTP
remain unknown, it is possible that the RAP motor tasks
selected for this study may have been NR2C containing and
NMDA-R independent, subverting any potential beneficial
effects of D-cycloserine.
Given that D-cycloserine can enhance certain models
of plasticity, such as long-term potentiation [57], and has
recently been investigated as an augmentation therapy for
psychological treatment procedures [58], we might expect
circulation NMDA-R to be associated with learning and
memory. This possibility was indeed observed, with the
partial Eta squared statistic indicating 37.6% of the variation
in SISmemory domain and 57.3% of the variation in improve-
ment in SIS hand function domain (Table 3(a)) could be
attributed to the D-cycloserine group. Our observations are
supported in that D-cycloserine has been shown to influence
emotional learning, being a potentiator of extinction of
conditioned fear in both animal models and human anxiety
disorders [18, 59, 60].
While the molecular basis for the behavioral effects of
D-cycloserine has not been elucidated, several clues exist as
to why D-cycloserine might have unique behavioral action
that other partial or full agonists at either the glycine or
glutamate binding site on the NMDA receptor appear to
lack. NMDA receptors are comprised of NR1, NR2A, and
NR2B subunits, and D-cycloserine at maximally effective
concentrations appears to cause slightly lower responses than
maximally effective levels of glycine (the endogenous ligand)
at NMDA receptors comprised of NR1/NR2A, NR1/NR2B,
and NR1/NR2D subunits. D-Cycloserine causes current
responses at NR1/NR2C receptors that are nearly twice as
large as glycine [61]. That is, D-cycloserine appears to selec-
tively enhance NMDA receptor function when the NR2C
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Table 3: ANCOVA table for (a) treatment group, (b) baseline
performance effect, and (c) treatment group × baseline performance
interaction for A-prime, reaction time, DETECT 𝑍-score, grip
strength, BBT, CES-D, and SIS categories. There was a significant
main effect of treatment group on the SIS affected hand function
domain.There was a significant main effect of baseline performance
onCES-D score and SISmemory,mood, affected hand function, and
social participation domain scores.Therewas a significant treatment
group × baseline performance interaction for SIS affected hand
function domain only.
(a) ANCOVA (per group)
Source 𝐹 𝑝 𝑝-RFDR 𝜂
𝑝
2
A-prime 0.003 0.959 1.812 0.000
Reaction time 0.041 0.844 1.594 0.005
DETECT 𝑍-score 0.730 0.421 0.795 0.094
Grip strength, affected hand 0.829 0.386 0.730 0.084
Grip strength, unaffected hand 0.405 0.540 1.020 0.043
BBT, affected hand 0.111 0.747 1.410 0.012
BBT, unaffected hand 1.884 0.203 0.384 0.173
CES-D score 0.092 0.769 1.452 0.010
Stroke Impact Scale Category
Strength 0.342 0.573 1.083 0.037
Memory 5.414 0.045 0.085 0.376
Mood 0.855 0.379 0.716 0.087
Communication 1.755 0.218 0.412 0.163
ADL/IADL 0.005 0.947 1.788 0.001
Mobility 0.536 0.483 0.912 0.056
Hand function 12.054 0.007 0.013 0.573
Participation 3.483 0.095 0.179 0.279
Stroke recovery 1.006 0.342 0.616 0.101
(b) ANCOVA (per baseline) across all subjects
Source 𝐹 𝑝 𝑝-RFDR 𝜂
𝑝
2
A-prime 0.978 0.348 0.658 0.098
Reaction time 6.427 0.032 0.060 0.417
DETECT 𝑍-score 4.256 0.078 0.147 0.378
Grip strength, affected hand 1.487 0.254 0.479 0.142
Grip strength, unaffected hand 1.541 0.246 0.464 0.146
BBT, affected hand 0.001 0.975 1.842 0.000
BBT, unaffected hand 5.576 0.043 0.080 0.383
CES-D score 15.197 0.004 0.007 0.628
Stroke Impact Scale Category
Strength 5.803 0.039 0.074 0.392
Memory 19.591 0.002 0.003 0.685
Mood 8.484 0.017 0.033 0.485
Communication 0.971 0.350 0.662 0.097
ADL/IADL 4.477 0.063 0.120 0.332
Mobility 0.934 0.359 0.678 0.094
Hand function 12.413 0.006 0.011 0.580
Participation 9.292 0.014 0.026 0.508
Stroke recovery 5.645 0.041 0.074 0.385
(c) ANCOVA (group ∗ baseline interaction)
Source 𝐹 𝑝 𝑝-RFDR 𝜂
𝑝
2
A-prime 0.001 0.980 1.852 0.000
(c) Continued.
Source 𝐹 𝑝 𝑝-RFDR 𝜂
𝑝
2
Reaction time 0.024 0.879 1.661 0.003
DETECT 𝑍-score 0.725 0.423 0.798 0.094
Grip strength, affected hand 0.009 0.926 1.750 0.001
Grip strength, unaffected hand 0.381 0.553 1.044 0.041
BBT, affected hand 0.724 0.417 0.787 0.074
BBT, unaffected hand 1.531 0.247 0.467 0.145
CES-D score 0.835 0.385 0.726 0.085
Stroke Impact Scale Category
Strength 0.202 0.663 1.253 0.022
Memory 3.667 0.088 0.166 0.290
Mood 1.082 0.325 0.615 0.107
Communication 1.423 0.263 0.498 0.136
ADL/IADL 0.025 0.877 1.656 0.003
Mobility 0.450 0.519 0.981 0.048
Hand function 11.771 0.007 0.013 0.567
Participation 3.882 0.080 0.151 0.301
Stroke recovery 0.302 0.596 1.073 0.032
subunit is available. This fact suggests that the unique behav-
ioral effects of D-cycloserine may be related to the potenti-
ation of NR2C-containing NMDA receptors. Implicit in the
hypotheses is the idea that enhancement of only NMDA
receptors that contain the NR2C subunit may enhance
emotional learning. In cortical structures (hippocampus and
neocortex), NR2C subunit mRNA is expressed in subset of
interneurons [53, 54] suggesting that modulation of NR2C
function has the potential to sculpt network activity through
modulation of interneuron firing. While the literature indi-
cates there is a molecular basis for D-cycloserine to act
as an enhancer through interneuron modulation [53, 54]
and positive effect on extinction based learning in humans
has been demonstrated [18, 60], our results indicate that
D-cycloserine does not have the same beneficial effects on
enhancing motor learning in our cohort of stroke survivors.
Additional research in animals and humans is needed to
clarify how D-cycloserine might enhance normal procedural
learning.
The RAP intervention showed greater improvement in
upper extremity motor function over the four-week period
independent of treatment arm. RAP has emerged in the last
decade and been promoted for restoring upper extremity
motor function in stroke survivors [2, 62–64]. One inter-
pretation of these results is that the action of repeatedly
moving the wrist and hand during RAP was the primary
stimulus to arm movement recovery for these participants.
This hypothesis is consistent with other repetitive-movement
exercise paradigms that improve upper extremity movement
ability following brain injury [65–67]. Sensorimotor path-
ways becomemore reliablewith repetitive activation aswould
be predicted by Hebbian learning [68]. Motor recovery seen
in all volunteers was enhanced due to the active-assist nature
of the robotic device. This observation corresponds well
to the robotic studies that have successfully used external
mechanical assistant to retrain arm ability after stroke.
Similar to other robot-assisted protocols [2], a major
advantage of this study was that the active therapy proto-
col was controlled for intensity, duration, and method of
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movements and improved consistency and reproducibility
of training. Both protocols included nine treatment sessions
and a large number of repetitions per session. As has been
suggested by others [2], the levels of improvement that
were observed in the two therapy groups during the 3-week
study suggest that high-intensity, repetitive, task-oriented
movement training may be necessary for motor recovery.
At present, we do not know whether a longer duration of
therapy or more repetitions per session could lead to more
meaningful results.
Between the two groups, there were a significantly greater
number of ≥10 change scores on SIS categories for the D-
cycloserine + RAP group compared with placebo + RAP
group, being 44.4% and 24.1%, respectively (odds ratio: 0.40,
95% CI: 1.063–5.988, 𝑝 = 0.036), and a significant degree
of association between the two variables (𝜙2 = 0.045, 𝑝 =
0.020). People randomized to theD-cycloserine + RAP group
were approximately 2.5 times as likely to exhibit a change
score of ≥10 SIS categories compared to people randomized
to the placebo + RAP group. Significant change in SIS hand
function and stroke recovery scores have been shown in
studies using a similar protocol [27]. A multicenter, random-
ized, controlled trial involving 127 patients with moderate
to severe upper limb impairment 6 months or more after
a stroke showed significant improvement in SIS categories
with robot-assisted therapy as compared with usual care but
found no significant benefit of robot-assisted therapy over
intensive comparison therapy at 12 weeks on Fugl-Meyer or
WMFT [2]. The lack of significant benefits of robot-assisted
therapy on FM and WMFT was attributed to a cohort of
patients with more severe impairments, who had multiple
strokes and who were enrolled at longer period of times
after stroke. Our participants were moderately impaired and
were randomized approximately a year from index stroke
compared to an average of 3.6 years from index stroke to
randomization in study of Lo et al. [2].
Another interpretation as to why no significant treatment
group differences were found may be that the preliminary
study lacked sufficient power to detect any significant effects
even if they exist in reality, which is reasonable given the
small sample size of 14. Nonetheless, even a cursory look at
the results indicates that moderately large differences exist
between means, so utilizing the current result for power
calculation of future studies appears to be justified. The
partial Eta2 results indicate the relative degree with which
the variance that was found in the ANOVA was associated
with each of the main effects (group and visit) and their
interaction. Partial Eta2 results can be interpreted as per-
centages of variance associated with each of the main effects,
the interaction, and error. Interpretation of these partial Eta2
results indicated over 29.5% of improvement in grip strength
of the affected hand, 27.5% improvement in memory, and
46.1% improvement in overall stroke recovery.
Many questions remain unanswered concerning the use-
fulness of D-cycloserine augmented physical therapy. For
example, additional dose-finding research in animals and
humans is needed to clarify howD-cycloserinemight interact
with other common medications. We did not exclude people
who were on anticoagulant, cholesterol, hypertension, or
diabetes therapy; and we did not screen antidepressant
and benzodiazepine medications. The augmenting effect of
D-cycloserine is potentially dependent on the timing and
number of doses. Administration of D-cycloserine for a
longer time (12 weeks versus 3 weeks) and using a longer
duration between administration and initiation of physio-
therapy (30min versus 20min) may lead tomoremeaningful
outcomes. Further studies will be needed to determine opti-
mal timing and duration of treatment, and it would need to be
determined whether the treatment produced an effect above
and beyond that achieved by robot-assisted physiotherapy
alone.
5. Conclusion
Across all patients in this study, significant improvements in
upper limb and other motor assessments were found over
time. At doses achieved in this trial, D-cycloserine + RAPwas
generally safe and well tolerated; however, this combination
did not show any improvement over and above the effects
of placebo + RAP. Given the substantial evidence base
demonstrating the role ofNMDAreceptor activity in learning
and memory and our own positive preliminary findings,
combining D-cycloserine with functional task practice may
help reinforce the involved motor pathways at the synaptic
level and thus enhance function performance over time.
Disclaimer
Thecontent is solely the responsibility of the authors and does
not necessarily represent the official views of the National
Institutes of Health.
Conflict of Interests
The authors certify that no party having a direct interest in
the results of the research supporting this paper has or will
confer a benefit on them or on any organization with which
the authors are associated and if applicable they also certify
that all financial and material support for this research (e.g.,
NIH, VA, or NHS grants) and work are clearly identified in
the title page of the paper.
Acknowledgments
The authors gratefully thank the therapists, coordinators,
and research assistants (Pawan Basati, DionneMiddlebrooks,
Erin O’Hara, David Wu, and Kimberly Richards) for invalu-
able work during data collection and analysis. This work was
supported by the National Center for Advancing Transla-
tional Sciences of the National Institutes of Health under
Award no. UL1TR000454.
References
[1] American Heart Association (AHA), Writing Group for the
Statistics Committee and Stroke Statistics Subcommittee: Heart
12 Rehabilitation Research and Practice
Disease and Stroke Statistics, American Heart Association,
Dallas, Tex, USA, 2005.
[2] A. C. Lo, P. D. Guarino, L. G. Richards et al., “Robot-assisted
therapy for long-term upper-limb impairment after stroke,”The
New England Journal of Medicine, vol. 362, no. 19, pp. 1772–1783,
2010.
[3] H. T. Hendricks, J. van Limbeek, A. C. Geurts, and M. J.
Zwarts, “Motor recovery after stroke: a systematic review of the
literature,” Archives of Physical Medicine and Rehabilitation, vol.
83, no. 11, pp. 1629–1637, 2002.
[4] J. D. Schaechter, “Motor rehabilitation and brain plasticity after
hemiparetic stroke,” Progress in Neurobiology, vol. 73, no. 1, pp.
61–72, 2004.
[5] M. Sivan, R. J. O’Connor, S. Makower, M. Levesley, and B.
Bhakta, “Systematic review of outcome measures used in the
evaluation of robot-assisted upper limb exercise in stroke,”
Journal of Rehabilitation Medicine, vol. 43, no. 3, pp. 181–189,
2011.
[6] C. E. Lang, J. R. MacDonald, D. S. Reisman et al., “Observation
of amounts of movement practice provided during stroke
rehabilitation,”Archives of Physical Medicine and Rehabilitation,
vol. 90, no. 10, pp. 1692–1698, 2009.
[7] S. Kavanagh, M. Knapp, and A. Patel, “Costs and disability
among stroke patients,” Journal of Public Health Medicine, vol.
21, no. 4, pp. 385–394, 1999.
[8] D. T. Wade, R. Langton-Hewer, V. A. Wood, C. E. Skilbeck, and
H. M. Ismail, “The hemiplegic arm after stroke: measurement
and recovery,” Journal of Neurology Neurosurgery and Psychia-
try, vol. 46, no. 6, pp. 521–524, 1983.
[9] A. Sunderland, D. Tinson, L. Bradley, and R. L. Hewer, “Arm
function after stroke. An evaluation of grip strength as a
measure of recovery and a prognostic indicator,” Journal of
Neurology, Neurosurgery & Psychiatry, vol. 52, no. 11, pp. 1267–
1272, 1989.
[10] P. W. Duncan, L. B. Goldstein, D. Matchar, G. W. Divine,
and J. Feussner, “Measurement of motor recovery after stroke.
Outcome assessment and sample size requirements,” Stroke, vol.
23, no. 8, pp. 1084–1089, 1992.
[11] A. Sunderland, D. J. Tinson, E. L. Bradley, D. Fletcher, R.
Langton Hewer, and D. T. Wade, “Enhanced physical therapy
improves recovery of arm function after stroke. a randomised
controlled trial,” Journal of Neurology Neurosurgery and Psychi-
atry, vol. 55, no. 7, pp. 530–535, 1992.
[12] R. H. Parry, N. B. Lincoln, and C. D. Vass, “Effect of severity of
arm impairment on response to additional physiotherapy early
after stroke,” Clinical Rehabilitation, vol. 13, no. 3, pp. 187–198,
1999.
[13] D. A. Nowak, C. Grefkes, M. Ameli, and G. R. Fink, “Interhemi-
spheric competition after stroke: brain stimulation to enhance
recovery of function of the affected hand,” Neurorehabilitation
and Neural Repair, vol. 23, no. 7, pp. 641–656, 2009.
[14] N. Bolognini, A. Pascual-Leone, and F. Fregni, “Using non-
invasive brain stimulation to augment motor training-induced
plasticity,” Journal of NeuroEngineering and Rehabilitation, vol.
6, article 8, 2009.
[15] M. K. O’Malley, T. Ro, and H. S. Levin, “Assessing and inducing
neuroplasticity with transcranial magnetic stimulation and
robotics for motor function,” Archives of Physical Medicine and
Rehabilitation, vol. 87, no. 12, supplement 2, pp. 59–66, 2006.
[16] A. Barria and R. Malinow, “NMDA receptor subunit com-
position controls synaptic plasticity by regulating binding to
CaMKII,” Neuron, vol. 48, no. 2, pp. 289–301, 2005.
[17] R. Yaka, A. Biegon, N. Grigoriadis et al., “D-cycloserine
improves functional recovery and reinstates long-term potenti-
ation (LTP) in amousemodel of closed head injury,”TheFASEB
Journal, vol. 21, no. 9, pp. 2033–2041, 2007.
[18] K. J. Ressler, B. O. Rothbaum, L. Tannenbaum et al., “Cognitive
enhancers as adjuncts to psychotherapy: use of D-cycloserine
in phobic individuals to facilitate extinction of fear,” Archives of
General Psychiatry, vol. 61, no. 11, pp. 1136–1144, 2004.
[19] W. F. Hood, R. P. Compton, and J. B. Monahan, “D-cycloserine:
a ligand for the N-methyl-d-aspartate coupled glycine receptor
has partial agonist characteristics,”Neuroscience Letters, vol. 98,
no. 1, pp. 91–95, 1989.
[20] G. B.Watson, M. A. Bolanowski, M. P. Baganoff, C. L. Deppeler,
and T. H. Lanthorn, “D-cycloserine acts as a partial agonist at
the glycine modulatory site of the NMDA receptor expressed
in Xenopus oocytes,” Brain Research, vol. 510, no. 1, pp. 158–160,
1990.
[21] B. L. Schwartz, S. Hashtroudi, R. L. Herting, P. Schwartz, and
S. I. Deutsch, “d-Cycloserine enhances implicit memory in
Alzheimer patients,”Neurology, vol. 46, no. 2, pp. 420–424, 1996.
[22] G. E. Tsai, W. E. Falk, J. Gunther, and J. T. Coyle, “Improved
cognition in Alzheimer’s disease with short-termD-cycloserine
treatment,” The American Journal of Psychiatry, vol. 156, no. 3,
pp. 467–469, 1999.
[23] K. M. Cherry, E. J. Lenze, and C. E. Lang, “Combining d-
cycloserine with motor training does not result in improved
general motor learning in neurologically intact people or in
people with stroke,” Journal of Neurophysiology, vol. 111, no. 12,
pp. 2516–2524, 2014.
[24] S. Y. Schaefer andC. E. Lang, “Using dual tasks to test immediate
transfer of training between naturalistic movements: a proof-
of-principle study,” Journal of Motor Behavior, vol. 44, no. 5, pp.
313–327, 2012.
[25] S. E. Nadeau, S. E. Davis, S. S. Wu, Y. Dai, and L. G. Richards,
“A pilot randomized controlled trial of D-cycloserine and dis-
tributed practice as adjuvants to constraint-induced movement
therapy after stroke,”Neurorehabilitation andNeural Repair, vol.
28, no. 9, pp. 885–895, 2014.
[26] S. L. Wolf, C. J. Winstein, J. P. Miller et al., “Effect of constraint-
induced movement therapy on upper extremity function 3 to 9
months after stroke: the EXCITE randomized clinical trial,”The
Journal of the AmericanMedical Association, vol. 296, no. 17, pp.
2095–2104, 2006.
[27] N. G. Kutner, R. Zhang, A. J. Butler, S. L. Wolf, and J. L. Alberts,
“Quality-of-life change associated with robotic-assisted therapy
to improve hand motor function in patients with subacute
stroke: a randomized clinical trial,” PhysicalTherapy, vol. 90, no.
4, pp. 493–504, 2010.
[28] J. L. Starkes and F. Allard, Cognitive Issues in Motor Expertise,
North-Holland, Amsterdam, The Netherlands, 1993.
[29] U. Hauben, R. D’Hooge, E. Soetens, and P. P. De Deyn, “Effects
of oral administration of the competitiveN-methyl-D-aspartate
antagonist, CGP 40116, on passive avoidance, spatial learning,
and neuromotor abilities in mice,” Brain Research Bulletin, vol.
48, no. 3, pp. 333–341, 1999.
[30] S. L. Wolf and S. A. Binder-Macleod, “Electromyographic
biofeedback applications to the hemiplegic patient. Changes in
upper extremity neuromuscular and functional status,” Physical
Therapy, vol. 63, no. 9, pp. 1393–1403, 1983.
[31] M. F. Folstein, S. E. Folstein, and P. R. McHugh, “‘Mini-mental
state’. A practical method for grading the cognitive state of
Rehabilitation Research and Practice 13
patients for the clinician,” Journal of Psychiatric Research, vol.
12, no. 3, pp. 189–198, 1975.
[32] S. G. Hofmann, M. H. Pollack, and M. W. Otto, “Augmentation
treatment of psychotherapy for anxiety disorders with D-
cycloserine,” CNS Drug Reviews, vol. 12, no. 3-4, pp. 208–217,
2006.
[33] S. L. Wolf, K. Sahu, R. C. Bay et al., “The HAAPI (Home Arm
Assistance Progression Initiative) trial: a novel robotics delivery
approach in stroke rehabilitation,”Neurorehabilitation&Neural
Repair, 2015.
[34] K. Wesnes and D. M.Warburton, “A comparison of temazepam
and flurazepam in terms of sleep quality and residual changes
in performance,”Neuropsychobiology, vol. 11, no. 4, pp. 255–259,
1984.
[35] J. T. Coull, H. C. Middleton, T. W. Robbins, and B. J. Sahakian,
“Clonidine and diazepam have differential effects on tests of
attention and learning,” Psychopharmacology, vol. 120, no. 3, pp.
322–332, 1995.
[36] P. W. Duncan, R. K. Bode, S. M. Lai, and S. Perera, “Rasch
analysis of a new stroke-specific outcome scale: the stroke
impact scale,” Archives of Physical Medicine and Rehabilitation,
vol. 84, no. 7, pp. 950–963, 2003.
[37] V. Mathiowetz, G. Volland, N. Kashman, and K. Weber, “Adult
norms for the Box and Block Test of manual dexterity,” Ameri-
can Journal of Occupational Therapy, vol. 39, no. 6, pp. 386–391,
1985.
[38] J. Higgins, N. M. Salbach, S. Wood-Dauphinee, C. L. Richards,
R. Coˆte´, and N. E. Mayo, “The effect of a task-oriented inter-
vention on arm function in people with stroke: a randomized
controlled trial,” Clinical Rehabilitation, vol. 20, no. 4, pp. 296–
310, 2006.
[39] A. Suputtitada, N. C. Suwanwela, and S. Tumvitee, “Effective-
ness of constraint-inducedmovement therapy in chronic stroke
patients,” Journal of the Medical Association of Thailand, vol. 87,
no. 12, pp. 1482–1490, 2004.
[40] D. M. Green and J. A. Swets, Signal Detection Theory and
Psychophysics, John Wiley & Sons, New York, NY, USA, 1966.
[41] J. B. Grier, “Nonparametric indexes for sensitivity and bias:
computing formulas,” Psychological Bulletin, vol. 75, no. 6, pp.
424–429, 1971.
[42] J. M. Barker, D. W. Wright, F. C. Goldstein, J. Ockerman, J. J.
Ratcliff, and M. C. Laplaca, “The DETECT system: portable,
reduced-length neuropsychological testing for mild traumatic
brain injury via a novel immersive environment,” Journal of
Medical Engineering & Technology, vol. 31, no. 3, pp. 161–169,
2007.
[43] P. J. Bayley, J. T. Wixted, R. O. Hopkins, and L. R. Squire,
“Yes/no recognition, forced-choice recognition, and the human
hippocampus,” Journal of Cognitive Neuroscience, vol. 20, no. 3,
pp. 505–512, 2008.
[44] E. Vellone, S. Savini, R. Fida et al., “Psychometric evaluation of
the stroke impact scale 3.0,” Journal of Cardiovascular Nursing,
vol. 30, no. 3, pp. 229–241, 2015.
[45] K.-C. Lin, T. Fu, C.-Y. Wu et al., “Minimal detectable change
and clinically important difference of the stroke impact scale in
stroke patients,” Neurorehabilitation and Neural Repair, vol. 24,
no. 5, pp. 486–492, 2010.
[46] H.-M. Chen, C. C. Chen, I.-P. Hsueh, S.-L. Huang, and C.-L.
Hsieh, “Test-retest reproducibility and smallest real difference
of 5 hand function tests in patients with stroke,” Neurorehabili-
tation and Neural Repair, vol. 23, no. 5, pp. 435–440, 2009.
[47] J. Cohen, Statistical Power Analysis for the Behavioral Sciences,
Lawrence Erlbaum Associates, Hillsdale, NJ, USA, 2nd edition,
1988.
[48] C. J. Ferguson, “An effect size primer: a guide for clinicians and
researchers,” Professional Psychology: Research and Practice, vol.
40, no. 5, pp. 532–538, 2009.
[49] J. W. Tukey, Exploratory Data Analysis, Addison-Wesley, 1977.
[50] S. F. Traynelis, L. P. Wollmuth, C. J. McBain et al., “Glutamate
receptor ion channels: structure, regulation, and function,”
Pharmacological Reviews, vol. 62, no. 3, pp. 405–496, 2010.
[51] K. Rosenkranz, A. Kacar, and J. C. Rothwell, “Differential
modulation of motor cortical plasticity and excitability in early
and late phases of human motor learning,” The Journal of
Neuroscience, vol. 27, no. 44, pp. 12058–12066, 2007.
[52] R. J. Fishkin, E. S. Ince, W. A. Carlezon Jr., and R. W. Dunn,
“D-cycloserine attenuates scopolamine-induced learning and
memory deficits in rats,” Behavioral and Neural Biology, vol. 59,
no. 2, pp. 150–157, 1993.
[53] A. M. Binshtok, I. A. Fleidervish, R. Sprengel, and M. J.
Gutnick, “NMDA receptors in layer 4 spiny stellate cells of the
mouse barrel cortex contain the NR2C subunit,”The Journal of
Neuroscience, vol. 26, no. 2, pp. 708–715, 2006.
[54] H. Monyer, N. Burnashev, D. J. Laurie, B. Sakmann, and P.
H. Seeburg, “Developmental and regional expression in the
rat brain and functional properties of four NMDA receptors,”
Neuron, vol. 12, no. 3, pp. 529–540, 1994.
[55] C. R. Scherzer, G. B. Landwehrmeyer, J. A. Kerner et al.,
“Expression of N-methyl-D-aspartate receptor subunit mRNAs
in the human brain: hippocampus and cortex,” Journal of
Comparative Neurology, vol. 390, no. 1, pp. 75–90, 1998.
[56] M. T. Hasan, S. Hernandez-Gonzalez, G. Dogbevia et al.,
“Role of motor cortex NMDA receptors in learning-dependent
synaptic plasticity of behaving mice,” Nature Communications,
vol. 4, article 2258, 2013.
[57] H. W. Kessels and R. Malinow, “Synaptic AMPA receptor
plasticity and behavior,” Neuron, vol. 61, no. 3, pp. 340–350,
2009.
[58] M. M. Norberg, J. H. Krystal, and D. F. Tolin, “A meta-analysis
of D-cycloserine and the facilitation of fear extinction and
exposure therapy,” Biological Psychiatry, vol. 63, no. 12, pp. 1118–
1126, 2008.
[59] D. L. Walker, K. J. Ressler, K.-T. Lu, and M. Davis, “Facilitation
of conditioned fear extinction by systemic administration or
intra-amygdala infusions ofD-cycloserine as assessedwith fear-
potentiated startle in rats,” Journal of Neuroscience, vol. 22, no.
6, pp. 2343–2351, 2002.
[60] S. G. Hofmann, A. E. Meuret, J. A. J. Smits et al., “Augmentation
of exposure therapy with D-cycloserine for social anxiety
disorder,” Archives of General Psychiatry, vol. 63, no. 3, pp. 298–
304, 2006.
[61] A. Sheinin, S. Shavit, and M. Benveniste, “Subunit speci-
ficity and mechanism of action of NMDA partial agonist D-
cycloserine,” Neuropharmacology, vol. 41, no. 2, pp. 151–158,
2001.
[62] R. Colombo, F. Pisano, S. Micera et al., “Assessing mechanisms
of recovery during robot-aided neurorehabilitation of the upper
limb,” Neurorehabilitation and Neural Repair, vol. 22, no. 1, pp.
50–63, 2008.
[63] S. Hesse, C.Werner,M. Pohl, S. Rueckriem, J.Mehrholz, andM.
L. Lingnau, “Computerized arm training improves the motor
control of the severely affected arm after stroke: a single-blinded
14 Rehabilitation Research and Practice
randomized trial in two centers,” Stroke, vol. 36, no. 9, pp. 1960–
1966, 2005.
[64] B. T. Volpe, H. I. Krebs, N. Hogan, L. Edelsteinn, C. M. Diels,
and M. L. Aisen, “Robot training enhanced motor outcome in
patients with strokemaintained over 3 years,”Neurology, vol. 53,
no. 8, pp. 1874–1876, 1999.
[65] C. M. Bu¨tefisch, H. Hummelsheim, P. Denzler, and K.-H.
Mauritz, “Repetitive training of isolated movements improves
the outcome of motor rehabilitation of the centrally paretic
hand,” Journal of the Neurological Sciences, vol. 130, no. 1, pp.
59–68, 1995.
[66] J. Liepert, H. Bauder, W. H. R. Miltner, E. Taub, and C. Weiller,
“Treatment-induced cortical reorganization after stroke in
humans,” Stroke, vol. 31, no. 6, pp. 1210–1216, 2000.
[67] R. J. Nudo, B.M.Wise, F. SiFuentes, andG.W.Milliken, “Neural
substrates for the effects of rehabilitative training on motor
recovery after ischemic infarct,” Science, vol. 272, no. 5269, pp.
1791–1794, 1996.
[68] D. O. Hebb,TheOrganization of Behavior; A Neuropsychological
Theory, Wiley, New York, NY, USA, 1949.



















































 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
